<DOC>
	<DOCNO>NCT00318799</DOCNO>
	<brief_summary>The aim study evaluate impact SH T00658ID ( EV/DNG tablet ) hemostatic parameter comparison reference oral contraceptive ( OC ) ( SH D01155E ) crossover design .</brief_summary>
	<brief_title>Impact SH T00658ID Compared Monophasic Contraceptive Containing Ethinylestradiol Levonorgestrel ( SH D01155E ) Hemostatic Parameters</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<criteria>Healthy female volunteer Pregnancy lactation Any condition might interfere outcome contraindication OC use .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>prevention unintended pregnancy</keyword>
</DOC>